MASCC Guidelines and Assessment Tools
©MASCC, Multinational Association for Supportive Care in Cancer™ • All rights reserved worldwide.
The MASCC/ESMO Antiemetic Guidelines have been updated in English as of January 2013. The guidelines are available in ten languages, obtained by the standard forward/backward translation process.
On behalf of the ESMO/MASCC Guidelines Working Group, the updated antiemetic guidelines have been published in the Annals of Oncology. Guideline update for MASCC and ESMO in the prevention of chemotherapy and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. F. Roila, J. Herrstedt, M. Aapro, R.J. Gralla, et al. , Annals of Oncology 21 (Supplement 5): v232 - v243, 2010
A major effort of the Mucositis Study Group of MASCC/ISOO has been a comprehensive review of the literature related to mucositis and the development of evidence-based clinical practice guidelines. The first set of MASCC/ISOO Mucositis Guidelines was published in the journal Cancer in 2004. The first update of these guidelines was described in publications in 2006 and 2007. The most recent update is now available here at the MASCC website: Mucositis Guidelines. This includes a summary paper published in Cancer 2014 and available via open access. In addition, a set of publications in Supportive Care in Cancer describes detailed results for different categories of interventions for mucositis. A summary of the guidelines is also posted.
MASCC Endorsed Guideline Partnerships
Acute AINV Guideline
The Pediatric Oncology Group of Ontario (POGO) has published “Guideline for the Prevention of Acute Nausea and Vomiting due to Antineoplastic Medication in Pediatric Cancer Patients” (April 2014). The purpose of this guideline is to provide healthcare providers with an approach to the prevention of acute antineoplastic-induced nausea and vomiting (AINV) in children. The scope is limited to the prevention of AINV in the acute phase (within 24 hours of antineoplastic administration). >> MORE
International Pediatric Fever and Neutropenia Guideline
The Hospital for Sick Children (SickKids.ca) published “Guideline for the Management of Fever and Neutropenia in Children With Cancer and/or Undergoing Hematopoietic Stem-Cell Transplantation” (September, 2012). Fever and neutropenia (FN) are common complications in children who receive chemotherapy for cancer. A panel of pediatric cancer and infectious disease experts developed an evidence-based guideline for empiric management of pediatric FN. The guideline focuses on children and adolescents with cancer and those with FN who are undergoing hematopoietic stem cell transplantation. Implementing the guideline requires adaptation to the local context and must take into account organizational barriers, such as available local infrastructure to support different models of care.
For more information contact:
Åge Schultz, DVM, PhD - MASCC Executive Director
Herredsvejen 2, DK-3400 Hillerød Denmark
Phone: +45 4820 7022; Fax: +45 4821 7022
MASCC Antiemesis Tool© (MAT)
The MASCC Antiemesis Tool© (MAT) was first created and posted in 2004. It is now available in several languages, obtained by the standard forward/backward translation process. The MAT was validated in 2007 by Molassiotis et al.* The MAT was developed by members of MASCC to assist patients and oncology professionals in communicating accurately about the prevention and control of nausea and vomiting associated with chemotherapy. The MAT provides a tool that is easy to use and evaluate, and that helps ensure the best patient care. Additionally, the tool can help treatment centers in understanding the effectiveness of antiemetic strategies. The MAT is available in print and as an iPhone/iPad app.
*Molassiotis A, Coventry PA, Stricker CT, Clements C, Eaby B, Velders L,Rittenberg C, Gralla RJ. Validation and psychometric assessment of a short clinical scale to measure chemotherapy-induced nausea and vomiting: the MASCC Antiemesis Tool. J Pain Symptom Manage. 2007 Aug; 34(2):148-159.
MASCC Oral Agent Teaching Tool© (MOATT)
The MASCC Oral Agent Teaching Tool© (MOATT) was developed by the MASCC Education Study Group to meet an identified need for healthcare providers involved in the education of patients receiving oral anticancer agents. The MOATT helps practitioners in providing comprehensive, standardized instruction. The MOATT provides a structured format to ensure that all key areas of patient assessment and teaching are addressed. It allows for individualization of teaching and uses evidence-based tenets in patient education. The MOATT has been cited in articles, used in research and quality improvement projects, and as an easy assist in patient education. The MOATT is both well researched and easy to use. It is available in several languages, translated via the standard forward/backward translation process.
MASCC EGFR Inhibitor Skin Toxicity Tool© (MESTT)
The MASCC EGFR Inhibitor Skin Toxicity Tool© (MESTT) was developed by the MASCC Skin Toxicity Study Group in 2008. It is intended to assist oncology health professionals with the monitoring and reporting of dermatologic adverse effects in patients treated with epidermal growth factor receptor (EGFR) inhibitors. The MESTT is an event-specific grading system that can be used to standardize assessment, optimize the use of EGFR inhibitors, and enable researchers to conduct more informative, controlled studies in this patient population.